{"nctId":"NCT01400698","briefTitle":"Saizen in Intra-uterine Growth Retardation","startDateStruct":{"date":"1998-11"},"conditions":["Children Born With Serious Intra-uterine Growth Retardation"],"count":91,"armGroups":[{"label":"Saizen® (Continuous or intermittent treatment)","type":"EXPERIMENTAL","interventionNames":["Drug: Saizen® A"]},{"label":"Saizen® (Observed and then continuous or no treatment)","type":"EXPERIMENTAL","interventionNames":["Drug: Saizen® B"]},{"label":"Observation only","type":"OTHER","interventionNames":["Other: Observation only"]}],"interventions":[{"name":"Saizen® A","otherNames":["r-hGH","Somatropin"]},{"name":"Saizen® B","otherNames":["r-hGH","Somatropin"]},{"name":"Observation only","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Previous inclusion, good compliance and normal completion of GF4001 or GF6283 in the treatment of growth failure in children born with serious IUGR (3-year continuous r-hGH treatment in GF4001 or 2-year continuous or intermittent r-hGH treatment in GF6283).\n* Increase in height greater than 0.5 standard deviation (SD) during the first 2 years of r-hGH treatment in GF4001 or after 2 years of continuous or intermittent r-hGH treatment in GF6283.\n* A written Informed Consent at the beginning of the pre-study visit must be obtained from the parent(s)/legal guardian(s), with the understanding that consent may be withdrawn by the subject or parents at any time without prejudice to their future medical care. Children able to understand the trial should personally sign and date the written informed consent, too.\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Known multiple malformation syndrome with severe psychomotor retardation and/or body hemihypertrophy.\n* Severe psychomotor retardation.\n* Severe congenital malformations.\n* Other protocol-defined exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Final Height","description":"Final height was defined as the height reached 1 year after height velocity (HV) was less than 2 centimeter/year (cm/year). Height velocity was the change in height since the previous year's measurement. Height was measured with a wall-mounted stadiometer (or in supine position if the participant's age was less than 3 years) and the measurement was repeated thrice by the same observer. The mean of the values obtained in the repeated measurements was taken for the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145.90","spread":"16.08"},{"groupId":"OG001","value":"150.06","spread":"12.89"},{"groupId":"OG002","value":"153.27","spread":"8.71"},{"groupId":"OG003","value":"155.59","spread":"8.38"}]}]}]},{"type":"PRIMARY","title":"Height Standard Deviation Score (HSDS)","description":"HSDS was calculated as height minus reference mean height divided by SD of the reference mean height, both given by the reference growth table (Sempe) for the corresponding chronological age at the height measurement. Greater HSDS indicate greater height. (Sempe M et al., 1979)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.45","spread":"0.76"},{"groupId":"OG001","value":"-1.90","spread":"1.73"},{"groupId":"OG002","value":"-2.33","spread":"1.01"},{"groupId":"OG003","value":"-1.99","spread":"0.88"}]}]}]},{"type":"SECONDARY","title":"Parental Adjusted Height Standard Deviation Score (PAHSDS)","description":"PAHSDS is the distance between the participant's current and target heights, expressed in units of SD of the height distribution of the reference population. Target height is a measure of the height which the participant could hypothetically reach based only on his parents' heights. Target height standard deviation score (THSDS) was calculated as target height minus mean adult height of the reference population divided by SD of the mean adult height of the reference population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.82","spread":"0.59"},{"groupId":"OG001","value":"-1.52","spread":"1.92"},{"groupId":"OG002","value":"-1.64","spread":"1.61"},{"groupId":"OG003","value":"-1.24","spread":"1.39"}]}]}]},{"type":"POST_HOC","title":"Duration of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.09","spread":"2.92"},{"groupId":"OG001","value":"4.51","spread":"2.20"}]}]}]},{"type":"POST_HOC","title":"Duration of Participation in the Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.08","spread":"2.27"},{"groupId":"OG001","value":"5.29","spread":"2.89"},{"groupId":"OG002","value":"4.10","spread":"2.87"},{"groupId":"OG003","value":"7.02","spread":"2.06"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":32},"commonTop":["Pharyngitis","Bronchitis","Headache","Gastroenteritis","Arthralgia"]}}}